Changeflow GovPing Pharma & Drug Safety Cμ4 Region for Multi-Specific Antibody Chain Pa...
Routine Notice Added Final

Cμ4 Region for Multi-Specific Antibody Chain Pairing

Favicon for changeflow.com USPTO Patent Applications - Peptides (C07K)
Published
Detected
Email

Summary

USPTO published patent application US20260098094A1 assigned to DNA Twopointo, Inc. covering multi-specific antibodies with IgM Cμ4 region pairing domains for correct heavy and light chain pairing. The invention promotes correct chain combinations and disfavors incorrect pairings in bispecific antibodies. The application was filed November 21, 2025.

What changed

USPTO published patent application US20260098094A1 for Cμ4 region-based chain pairing in multi-specific antibodies assigned to DNA Twopointo, Inc. The patent covers engineered antibodies where IgM Cμ4 region pairing domains promote correct heavy and light chain associations and reduce incorrect combinations.

This patent publication is informational and does not create compliance obligations. Parties developing bispecific antibody therapeutics may wish to review for potential freedom-to-operate implications or licensing opportunities. The technical scope is specific to IgM Cμ4 domain engineering for chain pairing.

What to do next

  1. Monitor for updates

Archived snapshot

Apr 12, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

Cµ4 REGION FOR PAIRING HEAVY AND LIGHT CHAINS IN MULTI-SPECIFIC ANTIBODIES

Application US20260098094A1 Kind: A1 Apr 09, 2026

Assignee

DNA Twopointo, Inc.

Inventors

Jeremy Minshull, Sridhar Govindarajan

Abstract

The invention provides multi-specific, for example bispecific, antibodies which include two different pairs of heavy and light chains, in which directed correct pairing of heavy and light chains is promoted by inclusion of an IgM Cμ4 region pairing domain, or a modified IgM Cμ4 region pairing domain. The IgM Cμ4 region pairs with a light chain kappa region or a CH1 region in one of the pairings. The other pairing is optionally a conventional CH1 and light chain constant region, or can be another pair of engineered binding domains. The IgM Cμ4 region and kappa or CH1 region preferentially associate with one another in the first pairing, and optionally, CH1 and light chain constant regions preferentially associate with each other in the other pairing thereby promoting correct combinations of heavy and light chain and disfavoring incorrect combinations.

CPC Classifications

C07K 16/2827 C07K 16/22 C07K 2317/31 C07K 2317/33 C07K 2317/522 C07K 2317/524 C07K 2317/526 C07K 2317/53 C07K 2317/72 C07K 2317/94

Filing Date

2025-11-21

Application No.

19396664

View original document →

Get daily alerts for USPTO Patent Applications - Peptides (C07K)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
April 9th, 2026
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
US20260098094A1

Who this affects

Applies to
Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent applications Antibody therapeutics Biotechnology research
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Healthcare Pharmaceuticals

Get alerts for this source

We'll email you when USPTO Patent Applications - Peptides (C07K) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!